Loxo

Loxo company information, Employees & Contact Information

Explore related pages

Related company profiles:

Loxo is the #1 Talent Intelligence Platform and global leader in recruiting software. But everyone says they're the best, don't they? That's why you've simply got to see for yourself. Loxo was designed to manage the full recruitment lifecycle in one, user-friendly platform. The Talent Intelligence Platform includes a best-in-class ATS, an AI-driven Recruiting CRM, a multi-channel outbound campaign product, a people and company search engine of over 1.2 billion people and millions of organizations, with verified contact information including mobile phone, personal and work emails, and instant AI sourcing, ranking and matching. All of these market leading products are designed to work seamlessly together in one unified end-to-end workflow. More than 13,200 Executive Search, RPO, professional recruitment and staffing teams across the globe use Loxo. Learn more at https://loxo.co/
Looking for a particular Loxo employee's phone or email?

Loxo Questions

News

Comet-like Co-MOF with TiO2 nanoparticles decorated used to efficiently activate peroxymonosulfate for larotrectinib degradation through radical and non-radical pathways - ScienceDirect.com

Comet-like Co-MOF with TiO2 nanoparticles decorated used to efficiently activate peroxymonosulfate for larotrectinib degradation through radical and non-radical pathways ScienceDirect.com

Lilly buys in another PI3Kα inhibitor | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Lilly buys in another PI3Kα inhibitor | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Lilly to acquire cancer biotech Scorpion, which shares a co-founder with Loxo - Endpoints News

Lilly to acquire cancer biotech Scorpion, which shares a co-founder with Loxo Endpoints News

FEATURE: Addressing middle-mile challenges with autonomous delivery - Parcel and Postal Technology International

FEATURE: Addressing middle-mile challenges with autonomous delivery Parcel and Postal Technology International

LOXO expands into Germany with self-driving logistics subsidiary - The Robot Report

LOXO expands into Germany with self-driving logistics subsidiary The Robot Report

Loxo Introduces a Proprietary Database Called Loxo Source™ Offering Recruiters Access to 510 Million People Across 12 Million Companies With Contact Information - PRWeb

Loxo Introduces a Proprietary Database Called Loxo Source™ Offering Recruiters Access to 510 Million People Across 12 Million Companies With Contact Information PRWeb

Metro Moves: Loxo Oncology opens Louisville lab - Denver Gazette

Metro Moves: Loxo Oncology opens Louisville lab Denver Gazette

How Swiss Startup LOXO is Overcoming Last Mile-Delivery Challenges - CEO Amin Amini - Auto Futures

How Swiss Startup LOXO is Overcoming Last Mile-Delivery Challenges - CEO Amin Amini Auto Futures

Executive of the Year: Josh Bilenker, Loxo Oncology - BioPharma Dive

Executive of the Year: Josh Bilenker, Loxo Oncology BioPharma Dive

Loxo Oncology at Lilly Announces Updated Data from the Phase 1/2 BRUIN Clinical Trial for LOXO-305 in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma at the American Society of Hematology Annual Meeting - PR Newswire

Loxo Oncology at Lilly Announces Updated Data from the Phase 1/2 BRUIN Clinical Trial for LOXO-305 in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma at the American Society of Hematology Annual Meeting PR Newswire

Loxo: Growth Investment Raised In $115 Million Deal For Advancing AI & Product Development - Pulse 2.0

Loxo: Growth Investment Raised In $115 Million Deal For Advancing AI & Product Development Pulse 2.0

Loxo Selects Aeva to Power Autonomous Delivery Vehicles - Business Wire

Loxo Selects Aeva to Power Autonomous Delivery Vehicles Business Wire

Eli Lilly to buy Loxo Oncology for $8 billion in huge bet on cancer genetics - statnews.com

Eli Lilly to buy Loxo Oncology for $8 billion in huge bet on cancer genetics statnews.com

Loxo Announces Free and Unlimited Personal Contact Information - PRWeb

Loxo Announces Free and Unlimited Personal Contact Information PRWeb

Lilly is down but not out of PI3K alpha inhibition | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Lilly is down but not out of PI3K alpha inhibition | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Loxo@Lilly Presents Updated Pirtobrutinib Data from the Phase 1/2 BRUIN Clinical Trial at the 2022 American Society of Hematology Annual Meeting - PR Newswire

Loxo@Lilly Presents Updated Pirtobrutinib Data from the Phase 1/2 BRUIN Clinical Trial at the 2022 American Society of Hematology Annual Meeting PR Newswire

Bayer to obtain full rights to global development and commercialization of oncology compounds Vitrakvi® (larotrectinib) and BAY 2731954 (LOXO-195) - PR Newswire

Bayer to obtain full rights to global development and commercialization of oncology compounds Vitrakvi® (larotrectinib) and BAY 2731954 (LOXO-195) PR Newswire

Loxo Oncology at Lilly Announces Updated Data from the Phase 1/2 BRUIN Clinical Trial for Pirtobrutinib at the American Society of Hematology Annual Meeting - PR Newswire

Loxo Oncology at Lilly Announces Updated Data from the Phase 1/2 BRUIN Clinical Trial for Pirtobrutinib at the American Society of Hematology Annual Meeting PR Newswire

Loxo Oncology at Lilly Announces Publication of Pirtobrutinib (LOXO-305) Phase 1/2 Data in The Lancet - PR Newswire

Loxo Oncology at Lilly Announces Publication of Pirtobrutinib (LOXO-305) Phase 1/2 Data in The Lancet PR Newswire

Swiss start-up LOXO presents market-ready autonomous vehicle for last mile delivery - PR Newswire

Swiss start-up LOXO presents market-ready autonomous vehicle for last mile delivery PR Newswire

Loxo Oncology at Lilly Announces Details of Presentations at 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics - PR Newswire

Loxo Oncology at Lilly Announces Details of Presentations at 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics PR Newswire

As Lilly deal closes, Bayer secures full rights to Loxo’s Vitrakvi - BioPharma Dive

As Lilly deal closes, Bayer secures full rights to Loxo’s Vitrakvi BioPharma Dive

Lilly to buy Loxo Oncology for $8B - BioPharma Dive

Lilly to buy Loxo Oncology for $8B BioPharma Dive

New Loxo@Lilly facility brings oncology research, development to Louisville - Colorado Hometown Weekly

New Loxo@Lilly facility brings oncology research, development to Louisville Colorado Hometown Weekly

New Loxo@Lilly facility brings oncology R&D to Louisville - BizWest

New Loxo@Lilly facility brings oncology R&D to Louisville BizWest

Bayer and Loxo Oncology to develop and commercialize two therapies that selectively target genetic drivers of cancer - PR Newswire

Bayer and Loxo Oncology to develop and commercialize two therapies that selectively target genetic drivers of cancer PR Newswire

Loxo to use InnovizOne Lidar in autonomous delivery vehicles - ITS International

Loxo to use InnovizOne Lidar in autonomous delivery vehicles ITS International

Lilly moves Loxo Oncology executives into new cancer R&D organization - MedCity News

Lilly moves Loxo Oncology executives into new cancer R&D organization MedCity News

The inside story of Eli Lilly's 18-day race to secure an $8 billion deal in time for the 'Super Bowl' of healthcare - businessinsider.com

The inside story of Eli Lilly's 18-day race to secure an $8 billion deal in time for the 'Super Bowl' of healthcare businessinsider.com

Aeva partners with Loxo for 4D LiDAR autonomous tech - Investing.com

Aeva partners with Loxo for 4D LiDAR autonomous tech Investing.com

Lilly’s Loxo buyout bears fruit as FDA clears cancer drug Retevmo - BioPharma Dive

Lilly’s Loxo buyout bears fruit as FDA clears cancer drug Retevmo BioPharma Dive

Loxo Oncology sold to Eli Lilly for $8 billion in cancer drug push - USA Today

Loxo Oncology sold to Eli Lilly for $8 billion in cancer drug push USA Today

Bayer, Loxo Win FDA Approval for Tumor-Agnostic Cancer Drug Vitrakvi - Genetic Engineering and Biotechnology News

Bayer, Loxo Win FDA Approval for Tumor-Agnostic Cancer Drug Vitrakvi Genetic Engineering and Biotechnology News

Loxo Oncology Announces Global Development and - GlobeNewswire

Loxo Oncology Announces Global Development and GlobeNewswire

Prepping for FDA filing, Loxo rolls up data on its site-agnostic cancer med larotrectinib - Fierce Biotech

Prepping for FDA filing, Loxo rolls up data on its site-agnostic cancer med larotrectinib Fierce Biotech

Stamford’s Loxo Oncology to be acquired in multibillion dollar deal - Stamford Advocate

Stamford’s Loxo Oncology to be acquired in multibillion dollar deal Stamford Advocate

[News] Loxo Selects Aeva to Power Autonomous Delivery Vehicles - LEDinside

[News] Loxo Selects Aeva to Power Autonomous Delivery Vehicles LEDinside

Founder of Stamford-based Loxo Oncology launches another biotech firm - Stamford Advocate

Founder of Stamford-based Loxo Oncology launches another biotech firm Stamford Advocate

JPM24: Lilly CEO David Ricks to biotechs: 'We're open for business' - Fierce Biotech

JPM24: Lilly CEO David Ricks to biotechs: 'We're open for business' Fierce Biotech

Scorpion Therapeutics debuts with $108M to 'put the sting in cancer' - Fierce Biotech

Scorpion Therapeutics debuts with $108M to 'put the sting in cancer' Fierce Biotech

Loxo Oncology announces billion-dollar deal with Bayer - Stamford Advocate

Loxo Oncology announces billion-dollar deal with Bayer Stamford Advocate

Bayer pays $400M upfront to buy into Loxo cancer drugs - Fierce Biotech

Bayer pays $400M upfront to buy into Loxo cancer drugs Fierce Biotech

Loxo And Bayer's Amazing Drug Has An Expensive Price - Forbes

Loxo And Bayer's Amazing Drug Has An Expensive Price Forbes

Pharma giant Eli Lilly just made an $8 billion bet on a cutting-edge scientific approach that uses DNA to treat cancer - businessinsider.com

Pharma giant Eli Lilly just made an $8 billion bet on a cutting-edge scientific approach that uses DNA to treat cancer businessinsider.com

The FDA just approved a drug that targets cancers based on DNA, rather than where the tumor is in your body - businessinsider.com

The FDA just approved a drug that targets cancers based on DNA, rather than where the tumor is in your body businessinsider.com

Eli Lilly and Loxo Oncology’s Promising Phase 3 Study Update on CLL/SLL Treatment - TipRanks

Eli Lilly and Loxo Oncology’s Promising Phase 3 Study Update on CLL/SLL Treatment TipRanks

Influential Women 2022: Nisha Nanda of Loxo@Lilly - The Business Journals

Influential Women 2022: Nisha Nanda of Loxo@Lilly The Business Journals

Wall Street Cheers Lilly's $8 Billion Loxo Deal for Cancer Drugs - Bloomberg.com

Wall Street Cheers Lilly's $8 Billion Loxo Deal for Cancer Drugs Bloomberg.com

LOXO introduces the first driverless delivery in Switzerland - Greater Geneva Bern area

LOXO introduces the first driverless delivery in Switzerland Greater Geneva Bern area

Top Loxo Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant